Rapid Micro Biosystems (RPID) AI Stock Analysis

• Market Cap: $138.82M
• Dividend Yield: N/A
• Average Volume (3M): 83.17K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.96
• Revenue Growth: 22.57%
• EPS Growth: 14.11%
• Country: US
• Employees: 163
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.27
• Shares Outstanding: 39,710,800
• 10 Day Avg. Volume: 90,537
• 30 Day Avg. Volume: 83,166
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.92
• Enterprise Value/Revenue: 4.24
• Enterprise Value/Gross Profit: 22.41
• Enterprise Value/Ebitda: -2.92
• 1Y Price Target: $8.00
• Price Target Upside: 173.04% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 45 Neutral
• Price Target: $3.00 ▲(2.39% Upside)

The overall stock score reflects significant financial challenges, including persistent losses and negative cash flows, which weigh heavily on the company's outlook. Technical indicators suggest mixed momentum, while valuation metrics highlight a challenging environment due to negative earnings. The earnings call provided some positive strategic developments, but ongoing market uncertainties and product margin challenges remain significant concerns.

Positive Factors

Revenue Growth

The consistent revenue growth, particularly in consumables and services, indicates strong demand and a robust business model, supporting long-term sustainability.

New Term Loan Facility

The new loan facility enhances financial flexibility, enabling strategic investments and supporting long-term growth objectives.

MilliporeSigma Partnership

The partnership with MilliporeSigma could lead to cost reductions and expanded market opportunities, strengthening competitive positioning.

Negative Factors

Product Margin Challenges

Negative product margins indicate ongoing cost issues, which could hinder profitability and require strategic adjustments to improve.

Operating Loss

Continued operating losses highlight challenges in achieving profitability, necessitating operational improvements to ensure long-term viability.

Uncertainty in System Placements

Uncertainty in system placements due to global trade dynamics may impact revenue growth, requiring strategic focus on market expansion.

Rapid Micro Biosystems Business Overview & Revenue Model

Company Description

Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in North America, Europe, and Asia. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides installation and verification, technical training, and support services. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. The company was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. Rapid Micro Biosystems, Inc. was incorporated in 2006 and is headquartered in Lowell, Massachusetts.

How the Company Makes Money

Rapid Micro Biosystems generates revenue through the sale of its Growth Direct System and related consumables, including proprietary growth media and software. The company operates on a recurring revenue model, benefiting from ongoing sales of consumables and maintenance services. Additionally, RPID partners with various pharmaceutical and biotech companies to provide customized solutions, which can lead to lucrative long-term contracts. The expansion of its customer base and the growing demand for rapid microbial testing in regulated industries contribute significantly to its earnings.

Rapid Micro Biosystems Financial Statement Overview

Summary

Rapid Micro Biosystems faces significant financial challenges, with persistent losses and negative cash flows. While revenue growth is present, profitability and cash generation remain critical issues. The balance sheet shows low leverage, which is a positive, but the company needs to address its operational inefficiencies to improve financial health.

Income Statement

Rapid Micro Biosystems shows a modest revenue growth rate of 2.17% TTM, but the company struggles with profitability as evidenced by negative margins across the board. The gross profit margin is low at 18.91%, and the net profit margin is significantly negative at -145.63%, indicating substantial losses. The EBIT and EBITDA margins are also deeply negative, reflecting operational challenges.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.10 TTM, suggesting conservative leverage. However, the return on equity is negative at -63.07%, indicating inefficiencies in generating returns from equity. The equity ratio stands at 72.15%, showing a strong equity base relative to total assets, which is a positive aspect.

Cash Flow

The cash flow situation is concerning, with negative operating and free cash flows. The free cash flow growth rate is negative at -132% TTM, highlighting deteriorating cash generation. The operating cash flow to net income ratio is -2.27, indicating cash flow challenges relative to net losses. However, the free cash flow to net income ratio is slightly positive at 1.03, suggesting some alignment between cash flow and accounting losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	30.29M	28.05M	22.52M	17.13M	23.23M	16.08M
Gross Profit	5.73M	-109.00K	-5.49M	-8.54M	-7.74M	-8.07M
EBITDA	-43.92M	-46.56M	-53.46M	-60.38M	-45.80M	-32.00M
Net Income	-44.11M	-46.89M	-52.47M	-60.81M	-73.52M	-37.08M
Balance Sheet
Total Assets	75.59M	98.17M	143.45M	190.65M	241.17M	70.00M
Cash, Cash Equivalents and Short-Term Investments	31.25M	50.73M	92.05M	108.65M	193.50M	45.08M
Total Debt	5.58M	6.17M	7.35M	7.97M	400.00K	24.81M
Total Liabilities	21.04M	22.82M	25.46M	26.48M	20.19M	45.18M
Stockholders Equity	54.55M	75.35M	117.99M	164.17M	220.98M	24.82M
Cash Flow
Free Cash Flow	-38.28M	-45.52M	-46.93M	-65.29M	-58.18M	-31.69M
Operating Cash Flow	-37.27M	-44.15M	-45.08M	-58.55M	-54.96M	-31.00M
Investing Cash Flow	18.35M	36.66M	42.15M	-93.47M	-13.29M	-15.67M
Financing Cash Flow	136.00K	203.00K	149.00K	693.00K	216.75M	64.23M

Rapid Micro Biosystems Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.93
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RPID, the sentiment is Negative. The current price of 2.93 is below the 20-day moving average (MA) of 3.34, below the 50-day MA of 3.01, and above the 200-day MA of 2.84, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 42.20 is Neutral, neither overbought nor oversold. The STOCH value of 29.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RPID.

Rapid Micro Biosystems Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SGHT	56 Neutral	$245.60M	―	-57.10%	―	-3.89%	9.68%
HYPR	53 Neutral	$102.16M	―	-77.26%	―	-9.59%	8.78%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LUCD	51 Neutral	$171.53M	―	-463.56%	―	14.74%	14.63%
RPID	45 Neutral	$138.82M	―	-59.15%	―	22.57%	14.11%
LUNG	45 Neutral	$68.05M	―	-66.88%	―	18.24%	4.81%
LNSR	42 Neutral	$146.56M	―	-350.22%	―	29.34%	-283.53%

Rapid Micro Biosystems Corporate Events

Rapid Micro Biosystems Secures $45M Loan for Growth

On August 8, 2025, Rapid Micro Biosystems entered into a Loan and Security Agreement with Trinity Capital Inc., securing a $45 million term loan facility to bolster its financial position and support long-term growth. The company reported a 10% increase in total revenue for the second quarter of 2025 compared to the previous year, driven by strong performance in service and product revenue, and reaffirmed its full-year revenue guidance of at least $32 million.

Rapid Micro Biosystems CEO Diagnosed with Lymphoma

On June 17, 2025, Robert Spignesi, CEO of Rapid Micro Biosystems, announced his diagnosis with a treatable form of Lymphoma. Despite the diagnosis and ongoing treatment, Spignesi plans to continue leading the company with limited in-person presence, expressing confidence in the company’s ability to maintain its performance and thanking the team for their support.